Particularly, trastuzumab-R27T had greater efficiency than trastuzumab or IFN-β-R27T alone in both NCI-N87 and YCC-19 humanized xenograft tumor models (Figures 8A,B). This evidence concerns the gene IFNB1 and neoplasm.